{"meta":{"totalResults":2,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"SI-B001"},{"type":"Synonym","name":"EGFR/HER3 bispecific antibody SI-B001"},{"type":"CodeName","name":"SIB001"},{"type":"CodeName","name":"SI B001"},{"type":"Synonym","name":"HER3 × EGFR SI-B001"},{"type":"Synonym","name":"anti-EGFR/anti-HER3 bi-specific monoclonal antibody SI-B001"},{"type":"CASRegistryName","name":"2559704-24-2"},{"type":"Synonym","name":"anti-EGFR/HER3 bispecific antibody SI-B001"},{"type":"Synonym","name":"HER3 x EGFR SI-B001"}],"definition":{"html":"An immunoglobulin G (IgG) bispecific antibody targeting both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon administration, izalontamab simultaneously targets and binds to EGFR and HER3 expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and HER3-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.","text":"An immunoglobulin G (IgG) bispecific antibody targeting both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon administration, izalontamab simultaneously targets and binds to EGFR and HER3 expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and HER3-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation."},"drugInfoSummaryLink":null,"nciConceptId":"C178396","nciConceptName":"Izalontamab","termId":804577,"name":"izalontamab","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"izalontamab"},{"aliases":[{"type":"CodeName","name":"BL-B01D1"},{"type":"CodeName","name":"BLB01D1"},{"type":"CodeName","name":"BL B01D1"},{"type":"Synonym","name":"ADC BL-B01D1"},{"type":"Synonym","name":"anti-EGFR/anti-HER3 ADC BL-B01D1"},{"type":"Synonym","name":"anti-EGFR/HER3 ADC BL-B01D1"},{"type":"Synonym","name":"dual antibody ADC BL-B01D1"},{"type":"Synonym","name":"dual target ADC BL-B01D1"}],"definition":{"html":"A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative and topoisomerase 1 inhibitor Ed-04, with potential antineoplastic activity. Upon administration of izalontamab brengitecan, the bispecific antibody moiety simultaneously targets and binds to EGFR and HER3 expressed on cancer cells. Upon binding and internalization, Ed-04 is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing EGFR and/or HER3. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. Simultaneously targeting both EGFR and HER3 may enhance the anti-tumor activity of izalontamab brengitecan.","text":"A dual-targeted antibody-drug conjugate (ADC) consisting of a bispecific antibody directed against both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a cathepsin-B cleavable linker, to the camptothecin derivative and topoisomerase 1 inhibitor Ed-04, with potential antineoplastic activity. Upon administration of izalontamab brengitecan, the bispecific antibody moiety simultaneously targets and binds to EGFR and HER3 expressed on cancer cells. Upon binding and internalization, Ed-04 is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing EGFR and/or HER3. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation. Simultaneously targeting both EGFR and HER3 may enhance the anti-tumor activity of izalontamab brengitecan."},"drugInfoSummaryLink":null,"nciConceptId":"C203048","nciConceptName":"Izalontamab Brengitecan","termId":809141,"name":"izalontamab brengitecan","firstLetter":"i","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"izalontamab-brengitecan"}],"links":null}